• Explore /
  • Poster
  • / KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

William R. Berry

Duke Cancer Center Cary, Cary, NC

William R. Berry , Peter C.C. Fong , Josep M. Piulats , Leonard Joseph Appleman , Henry Jacob Conter , Susan Feyerabend , Neal D. Shore , Gwenaelle Gravis , Brigitte Laguerre , Howard Gurney , Margitta Retz , Emanuela Romano , Loic Mourey , Johann S. De Bono , Audrey E. Kam , Urban Emmenegger , Helen Wu , Charles Schloss , Christian Heinrich Poehlein , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02861573

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 102)

Abstract #

102

Poster Bd #

E4

Abstract Disclosures

Similar Posters

First Author: Peter C.C. Fong

First Author: Christophe Massard

First Author: Peter C.C. Fong

First Author: Christophe Massard